Pfizer has announced, likely with a knowing grin, that the expected finding has come true that its old vaccine is less effective against the Omicron variant and that it will need another large government contract to create a new vaccine specifically designed for the Omicron variant, The Epoch Times reported.
Perhaps concerned that the Big Pharm cash-cow pandemic might be coming to an end, Pfizer CEO Albert Bourla assured investors and “consumers” that, if enticed with another federal contract, Pfizer can save us once more.
Bourla “predicted” this outcome earlier this year, suggesting that boosters and routine updates would become a basic necessity.
“A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination,” Bourla said in April. “But all of that needs to be confirmed. And again, the variants will play a key role.”
Bourla’s prophecy has now come true.
According to the CEO, the variants that he anticipated will require additional and routine vaccination, brought to you in part by Pfizer-BioNTech.
“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain,” Bourla said, “it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,”
“Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster,” he added, “remains the best course of action to prevent the spread of COVID-19.”
According to Dr. Ugur Sahin, BioNTech’s CEO, the Big Pharma pals are working with Biden’s Food and Drug Administration to bend the rules and roll out an adapted vaccine that would target Omicron.
That updated shot “will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine,” he said.
